Alpha Entrainment for Pain and Sleep (Extension)

January 14, 2025 updated by: Stephen Halpin, University of Manchester

Home-based Brainwave Entrainment Technology (hBET) for Management of Chronic Pain and Sleep Disturbance: EEG Extension to a Feasibility Study

Long-term pain affects one-third of the United Kingdom population and can be very disabling. People experiencing long-term pain often suffer from disturbed sleep because of their pain symptoms, and disturbed sleep can then make their pain symptoms worse. Managing long-term pain is also very costly to the National Health Service. The most common treatment is prescribed medicines, but these do not always work and can have serious side-effects for some patients.

The investigators have been developing an alternative approach for treating long-term pain. This approach uses simple non-invasive tools to promote some kinds of brain activity over others. It involves patients using headphones to listen to some specific sounds, or a headset with lights flashing at particular frequencies. The studies undertaken so far seem to show that doing this can change how the brain responds to pain. It potentially offers an inexpensive yet effective way of reducing pain and improving sleep for patients with long-term pain. There are a few small studies that support this approach and more work is needed. In a recent study the investigators found that these tools can be reliably used in home settings and there were some indications that they improved symptoms. However, sleep was only measured with sleep diary and movement detection, there was no direct measurement of whether the stimulation frequencies were resulting in the desired brainwave changes. Finally, the benefit to symptoms may have been the result of other factors, such as the passage of time or placebo effect.

Therefore this study extends the experiment, adding more accurate sleep monitoring which includes monitoring electrical activity in the brain (EEG), as well as providing rhythmic and non-rhythmic stimulation in a randomised order. The aim is to further test the effect of these home-based tools with individuals with long-term pain, in a more rigorous way. Up to 30 participants with long-term pain and pain-related sleep disturbance will use the tools for 30 minutes at bed time every day for 4 weeks (2 weeks with one type of stimulation, 2 weeks with another type). The changes in participants' pain, sleep, brainwave frequencies, fatigue and mood will be measured.

These findings will inform the planning and design of a future much larger study to test this technology, if this is justified by the results.

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Actual)

19

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Leeds, United Kingdom
        • Leeds Community Healthcare NHS Trust
    • England
      • Manchester, England, United Kingdom, M13 9PL
        • University Of Manchester

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 18-80 years
  • Chronic non-cancer pain (recurring pain ≥ 3 months duration)
  • Diagnosis of fibromyalgia, meeting 2016 ACR criteria.
  • Having nocturnal pain (NRS 0-10 worst pain ≥ 4)
  • Self-reported sleep difficulties (trouble falling asleep, difficulty staying asleep, waking up too early, or waking up unrefreshed) 3 or more nights per week during the past month

Exclusion Criteria:

  • Planned intervention during the study period
  • Seizure disorder
  • Photosensitivity
  • Hearing or sight problems causing inability to use hBET
  • Cognitive problems or dementia or mental health disorders causing inability to consent
  • Night shift worker
  • Any known primary sleep disorder including obstructive sleep apnoea, narcolepsy, restless leg syndrome

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: hBET 1
Rhythmic stimulation (2 weeks) followed by non-rhythmic stimulation (2 weeks)
Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation
Experimental: hBET 2
Non-rhythmic stimulation (2 weeks) followed by rhythmic stimulation (2 weeks)
Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in alpha power from baseline
Time Frame: Daily for 6 weeks
Alpha spectral power in active stimulation use periods compared to sham stimulation use periods relative to equivalent baseline periods.
Daily for 6 weeks
Change in Sleep Quality from baseline, measured with Pittsburgh Sleep Quality Index
Time Frame: Weeks 1, 3 and 6
Sleep quality (0-21 score) at the end of 2 week active stimulation use period compared to at the end of 2 week sham stimulation use period each relative to the baseline period.
Weeks 1, 3 and 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Daily pain diary
Time Frame: Daily for 6 weeks
pain over 24 hours and at night (0-10 NRS)
Daily for 6 weeks
Daily sleep diary; total sleep time
Time Frame: Daily for 6 weeks
Total sleep time (minutes)
Daily for 6 weeks
DREEM headband; total sleep time
Time Frame: Daily for 6 weeks
Total sleep time (minutes)
Daily for 6 weeks
Actigraphy; total sleep time
Time Frame: Daily for 6 weeks
Total sleep time (minutes)
Daily for 6 weeks
Daily sleep diary; sleep onset latency
Time Frame: Daily for 6 weeks
Sleep onset latency (minutes)
Daily for 6 weeks
DREEM headband; sleep onset latency
Time Frame: Daily for 6 weeks
Sleep onset latency (minutes)
Daily for 6 weeks
Actigraphy; sleep onset latency
Time Frame: Daily for 6 weeks
Sleep onset latency (minutes)
Daily for 6 weeks
Daily sleep diary; Wake after sleep onset
Time Frame: Daily for 6 weeks
Wake after sleep onset (minutes)
Daily for 6 weeks
DREEM Headband; Wake after sleep onset
Time Frame: Daily for 6 weeks
Wake after sleep onset (minutes)
Daily for 6 weeks
Actigraphy; Wake after sleep onset
Time Frame: Daily for 6 weeks
Wake after sleep onset (minutes)
Daily for 6 weeks
Daily sleep diary; Sleep Efficiency
Time Frame: Daily for 6 weeks
sleep efficiency (%)
Daily for 6 weeks
DREEM headband; Sleep Efficiency
Time Frame: Daily for 6 weeks
sleep efficiency (%)
Daily for 6 weeks
Actigraphy; Sleep Efficiency
Time Frame: Daily for 6 weeks
sleep efficiency (%)
Daily for 6 weeks
Daily sleep diary; Sleep quality
Time Frame: Daily for 6 weeks
Rating of quality (0-5 NRS) and refreshed (0-5 NRS)
Daily for 6 weeks
DREEM headband derived sleep architecture
Time Frame: Daily for 6 weeks
Duration in and latency to (minutes) and proportion (%) in each stage (N1, N2, N3, REM)
Daily for 6 weeks
DREEM headband derived microarousal index
Time Frame: Daily for 6 weeks
Microarousal frequency (events/hour)
Daily for 6 weeks
DREEM headband recorded awakenings
Time Frame: Daily for 6 weeks
Awakenings (number)
Daily for 6 weeks
Brief Pain Inventory Pain Interference score
Time Frame: Weekly for 6 weeks
0-10 NRS for pain interference
Weekly for 6 weeks
Brief Pain Inventory Severity score
Time Frame: Weekly for 6 weeks
0-10 NRS for pain severity
Weekly for 6 weeks
Hospital Anxiety and Depression Scale
Time Frame: Weeks 1, 3 and 6
Scores of 0-21 for anxiety, 0-21 for depression
Weeks 1, 3 and 6
Multidimensional Fatigue Inventory
Time Frame: Weeks 1, 3 and 6
Score of 20-100
Weeks 1, 3 and 6
EuroQol 5 Dimensions (EQ-5D-5L)
Time Frame: Weeks 1, 3 and 6
0-1 global index score, 0-100 VAS score.
Weeks 1, 3 and 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Anthony KP Jones, University Of Manchester

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 19, 2022

Primary Completion (Actual)

December 31, 2023

Study Completion (Actual)

December 31, 2024

Study Registration Dates

First Submitted

November 22, 2022

First Submitted That Met QC Criteria

January 16, 2023

First Posted (Actual)

January 26, 2023

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 14, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sleep Disturbance

Clinical Trials on Audio or visual alpha (10Hz) stimulation

Subscribe